Peter Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter Park has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Andrew M. Altman
Division of Plastic Surgery, Department of General Surgery Texas A&M Medical School - Baylor Scott & White Memorial Hospital Temple, TX, United States of America
1 shared publication- Biana Godin
Center for BioNanoengineering, Houston Methodist Hospital, Houston, USA
1 shared publication - Courtney Leonard
Division of Plastic and Oral Surgery, Baylor Scott and White Medical Center — Temple, McLane Children's Hospital, Temple, TX
1 shared publication - Ishan M. Mehta
Division of Plastic Surgery, Department of General Surgery Texas A&M Medical School - Baylor Scott & White Memorial Hospital Temple, TX, United States of America
1 shared publication - Jessica López Espinosa
Tecnológico de Monterrey, Mexico
1 shared publication Maya Ramy
Texas A&M College of Medicine Bryan Texas USA
1 shared publication
Latest Publications
- 19 September 2024
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 15 (12) , 997-1024
Nanotechnology-driven therapies for neurodegenerative diseases: a comprehensive review
Neurological diseases, characterized by neuroinflammation and neurodegeneration, impose a significant global burden, contributing to substantial morbidity, disability and mortality. A common feature of these disorders, including stroke, traumatic brain injury and Alzheimer's disease, is the impairment of the blood-brain barrier (BBB), a critical structure for maintaining brain homeostasis. The compromised BBB in neurodegenerative conditions poses a significant challenge for effective treatment, as it allows harmful substances to accumulate in the brain. Nanomedicine offers a promising approach to overcoming this barrier, with nanoparticles (NPs) engineered to deliver therapeutic agents directly to affected brain regions. This review explores the classification and design of NPs, divided into organic and inorganic categories and further categorized based on their chemical and physical properties. These characteristics influence the ability of NPs to carry and release therapeutic agents, target specific tissues and ensure appropriate clearance from the body. The review emphasizes the potential of NPs to enhance the diagnosis and treatment of neurodegenerative diseases through targeted delivery, improved drug bioavailability and real-time therapeutic efficacy monitoring. By addressing the challenges of the compromised BBB and targeting inflammatory biomarkers, NPs represent a cutting-edge strategy in managing neurological disorders, promising better patient outcomes.
- 19 September 2024
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 15 (12) , 997-1024
Nanotechnology-driven therapies for neurodegenerative diseases: a comprehensive review
Neurological diseases, characterized by neuroinflammation and neurodegeneration, impose a significant global burden, contributing to substantial morbidity, disability and mortality. A common feature of these disorders, including stroke, traumatic brain injury and Alzheimer's disease, is the impairment of the blood-brain barrier (BBB), a critical structure for maintaining brain homeostasis. The compromised BBB in neurodegenerative conditions poses a significant challenge for effective treatment, as it allows harmful substances to accumulate in the brain. Nanomedicine offers a promising approach to overcoming this barrier, with nanoparticles (NPs) engineered to deliver therapeutic agents directly to affected brain regions. This review explores the classification and design of NPs, divided into organic and inorganic categories and further categorized based on their chemical and physical properties. These characteristics influence the ability of NPs to carry and release therapeutic agents, target specific tissues and ensure appropriate clearance from the body. The review emphasizes the potential of NPs to enhance the diagnosis and treatment of neurodegenerative diseases through targeted delivery, improved drug bioavailability and real-time therapeutic efficacy monitoring. By addressing the challenges of the compromised BBB and targeting inflammatory biomarkers, NPs represent a cutting-edge strategy in managing neurological disorders, promising better patient outcomes.
- Open Access
- 24 May 2024
- Published by Elsevier in JPRAS Open
- Vol. 41, 116-127
The effect of a local anesthetic cocktail in a serratus anterior plane and PECS 1 block for implant-based breast reconstruction
- 24 May 2024
- Published by Elsevier in JPRAS Open
- Vol. 41, 116-127
Open AccessThe effect of a local anesthetic cocktail in a serratus anterior plane and PECS 1 block for implant-based breast reconstruction